Systemic chemotherapy for primary cutaneous b-cell lymphoma, leg-type: a case report
- 作者: Kamaeva I.1, Lysenko I.1, Nikolaeva N.1, Kapuza E.1, Pushkareva T.1, Lapteva T.1, Velichko A.1
-
隶属关系:
- National Medical Research Centre for Oncology
- 期: 卷 25, 编号 6 (2020)
- 页面: 213-218
- 栏目: Case Reports
- URL: https://journals.rcsi.science/1028-9984/article/view/77878
- DOI: https://doi.org/10.17816/1028-9984-2020-25-6-213-218
- ID: 77878
如何引用文章
详细
Primary cutaneous lymphomas are a group of extranodal B-cell non-Hodgkin’s lymphomas. Primary cutaneous diffuse B-large cell lymphoma, leg-type, is an extremely rare and aggressive variant of primary cutaneous lymphoma. Due to the contradictory nature, poor prognosis, and high frequency of recurrence of this disease, the treatment of patients is multidisciplinary, based on an accurate histological and immunohistochemical classification as well as risk factor assessment. In this report, we present a clinical case of primary cutaneous B-large cell skin lymphoma, leg-type, with a positive response to chemotherapy.
Clinical case. A clinical observation of chemotherapy of a patient with primary B-large cell skin lymphoma, leg-type, is presented. The patient underwent 6 R-CHOP chemotherapy courses and achieved an uncertain complete disease remission.
Conclusion. The results obtained confirm the limited literature data on the need for timely administration of systemic chemotherapy in the management of this pathology.
作者简介
Inna Kamaeva
National Medical Research Centre for Oncology
编辑信件的主要联系方式.
Email: inkamaeva@yandex.ru
ORCID iD: 0000-0003-3001-0675
младший научный сотрудник отдела лекарственного лечения опухолей
俄罗斯联邦, Rostov-on-DonIrina Lysenko
National Medical Research Centre for Oncology
Email: inkamaeva@yandex.ru
俄罗斯联邦, Rostov-on-Don
Nadezhda Nikolaeva
National Medical Research Centre for Oncology
Email: inkamaeva@yandex.ru
俄罗斯联邦, Rostov-on-Don
Elena Kapuza
National Medical Research Centre for Oncology
Email: inkamaeva@yandex.ru
俄罗斯联邦, Rostov-on-Don
Tatiana Pushkareva
National Medical Research Centre for Oncology
Email: inkamaeva@yandex.ru
俄罗斯联邦, Rostov-on-Don
Tatiana Lapteva
National Medical Research Centre for Oncology
Email: inkamaeva@yandex.ru
俄罗斯联邦, Rostov-on-Don
Alexey Velichko
National Medical Research Centre for Oncology
Email: inkamaeva@yandex.ru
俄罗斯联邦, Rostov-on-Don
参考
- Tadiotto Cicogna G, Ferranti M, Lazzarotto A, Alaibac M. Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas. Front Oncol. 2019;9:1238. doi: 10.3389/fonc.2019.01238
- Guskova NK, Selyutina ON, Novikova IA, et al. Morphological and immunofenotypic features of the monoclonal population of B-lymphocytes in chronic lymphocytic leukemia. South Russian Journal of Cancer. 2020;1(3):27-35. (In Russ). doi: 10.37748/2687-0533-2020-1-3-3
- Penskaya EA, Babaeva FE, Kravchenko SK, et al. Primary cutaneous diffuse b-large cell lymphoma, the leg type, with atypical clinical picture and indolent cours. Russian Journal Of Hematology And Transfusiology. 2015;60(4):41-44. (In Russ).
- Vitiello P, Sica A, Ronchi A, et al. Primary Cutaneous B-Cell Lymphomas: An Update. Front Oncol. 2020;10:651. doi: 10.3389/fonc.2020.00651
- Mitteldorf C, Berisha A, Pfaltz MC, et al. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets. Am J Surg Pathol. 2017;41(7):998-1004. doi: 10.1097/PAS.0000000000000851
- Gulia A, Saggini A, Wiesner T, et al. Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: implications for early diagnosis and treatment. J Am Acad Dermatol. 2011;65(5):991-1000. doi: 10.1016/j.jaad.2010.06.059
- Grange F, Joly P, Barbe C, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol. 2014;150(5):535-541. doi: 10.1001/jamadermatol.2013.7452
- Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9):3671-3678. doi: 10.1182/blood-2004-04-1594
- Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv30-iv40. doi: 10.1093/annonc/mdy133
- Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144-1150. doi: 10.1001/archderm.143.9.1144
- Ducharme O, Beylot-Barry M, Pham-Ledard A, et al. Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. J Invest Dermatol. 2019;139(11):2334-2342 e2338. doi: 10.1016/j.jid.2019.05.008
- Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-926. doi: 10.1038/nm.3884
- Kuo H-P, Hsieh S, Schweighofer KJ, et al. The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma. Blood. 2015;126(23):699-699. doi: 10.1182/blood.V126.23.699.699
- Fink-Puches R, Wolf IH, Zalaudek I, et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52(5):847-853. doi: 10.1016/j.jaad.2005.01.093
- Arkhipova OE, Chernogubova EA, Tarasov VA, et al. The level of oncological diseases as an indicator of medical-ecological safety of territories (the rostov region being exemplified). Vestnik Yuzhnogo nauchnogo tsentra RAN. 2013;9(3):7-14. (In Russ).